$TXG News

Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $37

Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $45

Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $42

Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $40

10x Genomics Partners With Cleveland Clinic Over Research In Novel Diagnostics For Bladder Cancer

10x Genomics: Temporary Pain, Long-Term Gain As Atera Rollout Approaches

10x Genomics Acquires Proteintech Genomics; Financial Terms Undisclosed

10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcript

10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.

The 5 Most Interesting Analyst Questions From 10x Genomics’s Q1 Earnings Call

10x Genomics, Inc. (TXG) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Is It Time To Reassess 10x Genomics (TXG) After Its Recent Share Price Surge?

Why 10x Genomics (TXG) Stock Is Down Today

A Look At 10x Genomics (TXG) Valuation After A Strong Year And Recent Share Price Pullback

Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $22

JP Morgan Maintains Neutral on 10x Genomics, Raises Price Target to $20

TXG Q1 Deep Dive: Atara Launch, Spatial Platform Transition, and AI-Driven Demand

10x Genomics Q1 Earnings Call Highlights

10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript

10x Genomics, Inc. Q1 2026 Earnings Call Summary